Head-to-head evidence
JMKX000623 vs Suzetrigine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Diabetic Peripheral Neuropathic Pain
Shared mechanism: Voltage-gated sodium channel NaV1.8 · full Diabetic Peripheral Neuropathic Pain pipeline
JMKX000623
Developed by Jemincare
NCT06221241 · Phase 2 · status unknown
This randomized, quadruple-blind, placebo- and active-comparator-controlled phase 2 trial in 220 people with diabetic peripheral neuropathic pain is designed to compare change in average daily pain score against placebo over 12 weeks. Results have not yet been posted.
Suzetrigine
Marketed by Vertex Pharmaceuticals
NCT05660538 · Phase 2 · completed
The trial randomized 194 participants to three suzetrigine doses or active-controlled pregabalin, using quadruple blinding and matched placebos; the primary endpoint was the clinical symptom measure of change in weekly average pain score. The reported within-group pain changes were similar across arms, but statistical significance for the between-group primary comparisons is not provided, so the result is unclear rather than definitively met.
Next expected readout: January 2027 · NCT06696443 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: JMKX000623's landscape · Suzetrigine's landscape